![](/img/cover-not-exists.png)
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
Leder, Benjamin, Zapalowski, Carol, Hu, Ming‐yi, Hattersley, Gary, Lane, Nancy E., Singer, Andrea J., Dore, Robin K.Language:
english
Journal:
Journal of Bone and Mineral Research
DOI:
10.1002/jbmr.3848
Date:
August, 2019
File:
PDF, 1.39 MB
english, 2019